Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Semen Test for Prostate Cancer May Improve Diagnosis, Study Says

Don't Miss Out —
Follow us on:

June 6 (Bloomberg) -- Semen contains prostate cancer biomarkers that could over time improve diagnosis of the condition, a group of Australian researchers said.

After analyzing seminal fluid samples from 60 men, the researchers discovered tiny molecules called microRNAs known to be elevated in prostate cancer. Some of the molecules were “surprisingly accurate” in detecting the cancer and its severity, according to a study published in the journal Endocrine-Related Cancer.

The results could help spot the disease, which is now often diagnosed with the prostate specific antigen, or PSA, test. That type of blood testing has resulted in substantial over diagnosis and over treatment without having a significant effect on prostate cancer mortality, according to the researchers.

“While the PSA test is very sensitive, it is not highly specific for prostate cancer,” said Luke Selth, a research fellow at the University of Adelaide and the lead author of the study. “We have a long way until we can potentially use these biomarkers in a clinical test -- but it’s a promising development.”

Prostate cancer is the second most common cancer in American men, after skin cancer. An estimated 233,000 new cases of prostate cancer will be diagnosed in the U.S. this year and the disease will kill about 29,480 patients, according to the National Cancer Institute.

“We certainly do need better biomarkers for prostate cancer and the results in this study are of interest,” said Declan G. Murphy, a uro-oncologist and associate professor at the Peter MacCallum Cancer Center in East Melbourne, Australia. “Seminal fluid however, is not the most convenient of targets for a biomarker and this finding would have more practical impact if it could be demonstrated in serum also.”

The findings will need to be validated in a larger and more diverse cohort, Selth said.

To contact the reporter on this story: Natasha Khan in Hong Kong at nkhan51@bloomberg.net

To contact the editors responsible for this story: Anjali Cordeiro at acordeiro2@bloomberg.net Angela Zimm

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.